177-Lutetium-PSMA-I&T
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 177-Lutetium-PSMA-I&T, covering 2026-01-05 to 2026-01-05. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma [Phase 1]